The mechanisms involved in the development of alcoholic liver disease (ALD) are not well-established. We investigated the involvement of acyl-CoA: diacylglycerol acyltransferase 2 (DGAT2) upregulation in mediating hepatic fat accumulation induced by chronic alcohol consumption. Chronic alcohol feeding caused fatty liver and increased hepatic DGAT2 gene and protein expression, concomitant with a significant suppression of hepatic MEK/ERK1/2 activation. In vitro studies demonstrated that specific inhibitors of the MEK/ERK1/2 pathway increased DGAT2 gene expression and triglyceride (TG) contents in HepG2 cells, while epidermal growth factor, a strong ERK1/2 activator, had the opposite effect. Moreover, chronic alcohol feeding decreased hepatic S-adenosylmethionine (SAM): S-adenosylhomocysteine (SAH) ratio, an indicator of disrupted transmethylation reactions. Mechanistic investigations revealed that N-acetyl-S-farnesyl-L-cysteine, a potent inhibitor of isoprenylcysteine carboxyl methyltransferase, suppressed ERK1/2 activation, followed by an enhanced DGAT2 expression and an elevated TG content in HepG2 cells. Lastly, we demonstrated that the beneficial effects of betaine supplementation in ALD were associated with improved SAM/SAH ratio, alleviated ERK1/2 inhibition, and attenuated DGAT2 upregulation. In conclusion, our data suggest that upregulation of DGAT2 plays an important role in the pathogenesis of ALD, and that abnormal methionine metabolism contributes, at least partially, to DGAT2 upregulation via suppression of MEK/ERK1/2 activation. 
INTRODUCTION
Alcoholic liver disease (ALD) continues to be an important health problem in the United States.
Although much progress has been made over the past two decades, the mechanisms involved in its initiation and progression remain to be fully understood. The disease is characterized by early steatosis, subsequent steatohepatitis (steatosis with inflammatory cell infiltration and necrosis), and, in some instances, progression to fibrosis and/or cirrhosis (1, 2) . Excessive neutral fat accumulation in hepatocytes (steatosis) is the most common and earliest response of the liver to chronic alcohol consumption (3) and plays a critical role in disease progression. Hepatic steatosis results from an imbalance between intrahepatic triglyceride (TG) production and removal. Both uptake of free fatty acids (FA) to the liver and de novo synthesis contribute to hepatic TG production, while FA beta-oxidation and formation of very low-density lipoprotein (VLDL) particles contribute to hepatic TG removal.
The final step and rate-limiting reaction in TG synthesis is catalyzed by acyl CoA:diacylglycerol acyltransferase (DGAT), which covalently joins a fatty acyl-CoA and a diacylglycerol (DG) molecule to form TG. In mammals, DGAT occurs in two isoforms, DGAT1 and DGAT2, from distinct gene families (4, 5) . Although both isoforms are widely expressed and present at high levels in white adipose tissue, DGAT1 is most highly expressed in the small intestine, whereas DGAT2 is primarily expressed in the liver (4, 6) .
Evidence suggest that the two enzymes play different roles in TG metabolism, with DGAT2 participating in steatosis and DGAT1 in VLDL synthesis. Overexpression of liver-specific DGAT2 in mice results in hepatic steatosis (7) . Conversely, inhibition of DGAT2 with antisense oligonucleotides reverses hepatic steatosis in ob/ob mice and in mice challenged with high-fat diet (8) (9) (10) , suggesting that this enzyme plays a critical role in the development of fatty liver disease. Although strong evidence supports that fatty liver development induced by chronic alcohol consumption is secondary to increased de novo synthesis, the effect of alcohol exposure on DGAT regulation remains to be clarified.
Disrupted methionine metabolism plays a pathological role in ALD (11) (12) (13) (14) (15) . S-adenosylmethionine (SAM) is the first product in the methionine metabolic pathway and a universal methyl donor. After donating its methyl group for transmethylation reaction, SAM is converted into S-adenosylhomocysteine (SAH), which is subsequently hydrolyzed to homocysteine and adenosine. In turn, SAH is a potent inhibitor of most known methyltransferases. Alcohol-induced abnormal methionine metabolism is characterized by disrupted transmethylation reactions due to decreased SAM and increased SAH levels and affects numerous signaling pathways involved in apoptosis, regeneration, and lipid metabolism. Among these is the Ras/ERK1/2 pathway. The extracellular signal-regulated kinases 1 and 2 (ERK1/2) are members of the mitogen-activated protein kinase (MAPK) family, whose activation results in cell growth, proliferation, survival, and inflammation (16) . The activation of ERK1/2 is strongly dependent on the GTPase Ras, whose activity requires association with cellular membranes (17, 18) . Ras plasma membrane association requires a series of posttranslational modifications of its carboxyl terminus, including farnesylation, proteolysis, and methylation of its CAAX sequence. The methylation reactions require SAM as a methyl group donor to produce methylated Ras. In this context, ERK1/2 activation is closely related to methionine metabolism.
We previously reported that ERK1/2 phosphorylation reduced in the liver of alcohol-fed rats, and this is associated with hypercholesterolemia and reduced hepatic low-density lipoprotein (LDL) receptor expression, suggesting that the ERK1/2 pathway participates in the regulation of hepatic lipid metabolism (19) . In the present study, we conducted in vivo and in vitro experiments to investigate the role of DGAT2 upregulation in the development of hepatic steatosis in alcohol-fed mice and the potential mechanistic involvement of suppression of the MEK/ERK1/2 pathway in DGAT2 upregulation.
MATERIALS AND METHODS

Animals and Treatments
Male C57BL/6 mice weighing 25 ± 0.5 g (means ± SD) were obtained from the Jackson Laboratory (Bar Harbor, ME). Studies were approved by the Institutional Animal Care and Use Committee, which is certified by the American Association of Accreditation of Laboratory Animal Care. Eight mice were randomly assigned to two groups and fed for four weeks with liquid diets containing (in percent of energy intake) 18% protein, 35% fat, 12% carbohydrate, and 35% either ethanol (alcohol-fed, AF) or an isocaloric maltose-dextrin mixture (pair-fed, PF), according to Lieber and De Carli (20) . Food intake and body weight were recorded daily and weekly, respectively. For betaine supplementation, betaine (anhydrous; Sigma, St.
Louis, MO) was supplemented in the alcohol-containing liquid diet (1%, w/v) and started simultaneously with AF diet. Mice were euthanized and plasma and liver tissue samples harvested at the end of the experiment.
Cells and Culture Conditions
HepG2 cells, a human hepatoma cell line, were obtained from the American Type Culture Collection (ATCC, Manassas, VA) and cultured in DMEM containing 10% (v/v) fetal bovine serum, 2mM glutamine, 5U/ml penicillin, and 50ȝg/ml streptomycin at 37 °C in a humidified O 2 /CO 2 (19:1) atmosphere.
Plasma Biochemical Assays
Plasma levels of alanine aminotransferases (ALT) and TG were assayed using commercially available kits (Infinity, Thermo Electron, Melbourne, Australia).
Liver TG Measurements
For intrahepatic TG measurement, liver tissues (~80mg) were homogenized in 1.0ml NaCl (50mM) solution and hepatic total lipids were extracted overnight in 10 ml heptane:isopropanol (3:2) mixture at 4ºC. Hepatic TG content was determined by enzymatic colorimetric methods using a commercially available kit (Infinity, Thermo Electron, Melbourne, Australia).
Measurement of Methionine Metabolites
Liver tissue was homogenized and deproteinized in 4% metaphosphoric acid (1:8, m/v). The homogenates were centrifuged at 15,000g for 10 minutes. SAM and SAH were determined via a high-performance liquid chromatography (HPLC) method using a 5-mm Hypersil C-18 column (250 × 4.6 mm). The mobile phase consisted of 40mM ammonium phosphate, 8mM heptane sulfonic acid [ion-pairing reagent (pH 5.0)], and 6% acetonitrile, and was delivered at a flow rate of 1.0ml/minute. SAM, SAH, betaine and GSH were detected using a Waters 740 UV detector at 254nm. An internal standard, S-adenosylethionine, was added to all samples and standard solutions to a concentration of 100μM.
Measurement of Intracellular TG Content
To determine the intracellular TG content, HepG2 cells seeded in 24-well plates were washed twice with phosphate buffered saline (PBS) and cellular lipids were extracted by 1ml hexane:isopropanol (3:2) mixture.
TG content was measured using a TG assay kit (Infinity, Thermo Electron, Melbourne, Australia). Cells undergoing the same treatment conditions were lysed in RIPA buffer for protein concentration determination and data normalization. 
Measurement of DGAT2 Activity
The microsomal fraction from HepG2 cells was prepared as described previously (38) . Because DGAT2
activity is inhibited at high concentrations of MgCl 2 (100mM), the DGAT assay was carried out in the presence of 8mM and 100mM MgCl 2 and DGAT2 activity was calculated by subtracting the value obtained All data are expressed as means ± SD. Statistical analysis was performed using a one-way ANOVA and further analyzed by Newman-Keuls test for statistical difference. Differences between treatments were considered to be statistically significant at P < 0.05.
Statistical Analysis
RESULTS
Chronic Alcohol Exposure Increased Hepatic DGAT2 Gene Expression and Protein Production
Chronic alcohol consumption for 4 weeks caused fatty liver and liver injury, as evidenced by significantly increased plasma ALT levels, increased liver weight vs. body weight ratio, and elevated liver TG content in the alcohol-fed group (data not shown). Long-term AF increased DGAT2 gene (Fig. 1A ) and protein expression ( 
Chronic Alcohol Exposure Resulted in ERK1/2 Suppression in the Liver
To examine the effect of AF on MAPK activation in the liver, we conducted immunoblotting analysis using total liver tissue extracts from both PF and AF mice. As shown in Figure 2 , AF had no effect on JNK activation ( Fig. 2A) , while the activation of p38 was minimally enhanced (Fig. 2B) . However, AF resulted in a significant reduction in the phosphorylation of ERK1/2 ( Fig. 2C & D) , which was in line with our previous observation in rats (19) . No changes in protein levels of the three members of the MAPK family were observed in the liver of AF animals when compared with PF controls.
Chronic Alcohol Exposure Caused Abnormal Methionine Metabolism in the Liver
To determine the effects of AF on methionine metabolism in the liver, we measured SAM, SAH, betaine, and glutathione (GSH) concentrations in the liver via HPLC. In line with our previous reports, AF significantly decreased hepatic SAM levels, while hepatic SAH levels were significantly elevated, leading to a significantly decreased SAM/SAH ratio. Liver betaine levels decreased slightly in AF, while GSH levels in the liver significantly decreased (table 1) .
MEK/ERK1/2 Inhibition Leads to Increased Intracellular TG Accumulation in Hepatocytes
To determine if ERK1/2 inhibition was associated with increased TG accumulation in the liver, we treated HepG2 cells with two specific inhibitors of the MEK/ERK1/2 pathway, U0126 (10μM) and PD98059 (10μM), before challenging cells with oleic acid. Intracellular TG levels were assayed 20 hours later. As shown in Fig. 3 , both inhibitors significantly increased intracellular TG content (Fig. 3A) . To examine whether TG accumulation could be prevented by enhancing ERK1/2 activation, we treated HepG2 cells with EGF (100ng/ml), an activator of ERK1/2 signaling, prior to oleic acid challenge. EGF treatment reduced intracellular TG content (Fig. 3B) , which was associated with enhanced ERK1/2 activation (Fig.   3C ).
MEK/ERK1/2 Suppression Upregulated DGAT2 expression and activity in HepG2 Cells
To test whether hepatic ERK1/2 inhibition affected DGAT2 expression, gene and protein expression and DGAT2 activity were measured. Exposure to the ERK1/2 inhibitor U0126 (10μM) resulted in an approximate 5-fold increase in DGAT2 mRNA expression in HepG2 cells compared with the untreated group (Fig. 3D) . In contrast, enhanced ERK1/2 activation by EGF (100ng/ml) decreased DGAT2 mRNA levels (Fig. 3E) . Moreover, exposure of cells to U0126 to inhibit ERK1/2 activation significantly increased DGAT2 enzymatic activity (Fig. 3F) . Furthermore, transfection of HepG2 cells with DGAT2 siRNA, which caused an 80% decrease in DGAT2 mRNA expression, significantly decreased intracellular TG levels ( Fig.   4A & B) . Accordingly, treatment with DGAT2 siRNA completely prevented U0126-induced intracellular TG increase in HepG2 cells (Fig. 4B) , implying that upregulation of DGAT2 contributes to the increased hepatic TG content by ERK1/2 inhibition.
Inhibition of Methyltransferase Suppressed MEK/ERK1/2 Activation, Enhanced DGAT2 Expression, and Elevated TG Contents in HepG2 Cells
In order to determine whether inhibition of transmethylation reactions was related with hepatic ERK1/2 inhibition and DGAT2 induction, we applied N-acetyl-S-farnesyl-L-cysteine (AFC), an inhibitor of SAM-dependent methyltransferases (specific for isoprenylcysteine carboxyl methyltransferase, ICMT), to HepG2 cells. Result showed that treatment with AFC (from 10μM to 40μM) for 24 hours decreased ERK1/2 phosphorylation in a dose-dependent fashion (Fig. 5A ). In addition, AFC significantly augmented intracellular TG levels (Fig. 5B ) and DGAT2 gene expression (Fig. 5C ) when compared with the untreated group.
The Beneficial Effect of Betaine in ALD was Associated with Improved Methionine Metabolism,
Alleviated ERK1/2 Inhibition, and Attenuated DGAT2 Induction in the Liver
Betaine exerts beneficial effects on fatty liver diseases by improving methionine metabolism. In an attempt to elucidate the mechanisms for the beneficial effect of betaine in ALD, betaine, at a dose of 1% (v/w), was supplemented in the alcohol-containing liquid diet. Four weeks later, we found that betaine supplementation prevented alcohol-induced fatty liver and liver injury, as evidenced by lowered TG content in the liver (Fig.   6A ) and ALT levels in plasma (Fig. 6B ), which were associated with significantly improved hepatic methionine metabolism (Table 1) . Data showed that the beneficial effect of betaine supplementation was associated with alleviated ERK1/2 inhibition and attenuated DGAT2 induction ( Fig. 6C-E) in the liver. ERK1/2-regulated pathways play an important role in controlling lipid metabolism in the liver (24, 25) .
We and others previously reported that chronic alcohol exposure causes significant MEK/ERK1/2 suppression in the liver (19, 31, 32) . In the present study, we demonstrate that alcohol-induced hepatic MEK/ERK1/2 suppression is associated with increased DGAT2 expression and protein production. In vitro studies reveal that specific inhibition of MEK/ERK1/2 activation increases gene expression and factor and augmented inflammatory responses (28, 29) . It has also been well documented that acute exposure to alcohol results in modest activation of ERK1/2 in hepatocytes (30), whereas chronic alcohol exposure suppresses both constitutive and growth factor-stimulated ERK1/2 activation in the liver (31) (32) .
The mechanisms involved in MEK/ERK1/2 inhibition by chronic alcohol exposure are not well understood and are probably multifactorial. The ethanol-induced lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) has been reported to be an upstream modulator of ERK1/2 activation (31). Inhibition of the insulin receptor substrate 1 (IRS-1) signaling pathway by chronic alcohol consumption may also contribute to suppressed ERK1/2 activation in the liver (32) . The Ras/Raf/MEK/ERK1/2 pathway is the major signal transduction pathway for ERK1/2 activation, which is strongly dependent on the GTPase Ras, whose activity requires its association with cellular membranes (17, 18) . Ras plasma membrane association requires a series of posttranslational modifications of its carboxyl terminus, including farnesylation, proteolysis, and methylation of its CAAX sequence. These modifications allow CAAX proteins to associate with cellular membranes and promote protein-protein interactions (33) . The methylation reactions require SAM as a methyl group donor to produce methylated Ras, thus linking methionine metabolism to modulation of MEK/ERK1/2 activation. Indeed, intracellular SAH level is negatively related to ICMT activity (34) . In addition, 3-Deazaadenosine, a potent inhibitor of S-adenosylhomocysteine hydrolase, whose inhibition induces intracellular SAH accumulation, prevents vascular smooth muscle cell proliferation and neointima formation by interfering with Ras methylation and thereby with mitogenic activation of ERK1/2 (35) . Abnormalities in hepatic methionine metabolism are well documented in ALD.
Decreased phosphatidylethanolamine methyltransferase (PEMT) activity due to disrupted transmethylation reactions and subsequently decreased phosphatidylcholine synthesis contributes to alcohol-induced fatty liver via suppressing VLDL formation and secretion. In agreement with this observation, improvement of methionine metabolism by betaine supplementation alleviates PEMT suppression and attenuates alcoholic fatty liver (36) . In line with previous studies, our results show that chronic alcohol exposure is associated with suppressed hepatic transmethylation reactions, evidenced by decreased SAM and increased SAH levels in the liver, leading to a significantly decreased SAM:SAH ratio. In the present study we examined whether inhibition of methylation reactions could also modulate ERK1/2 activation in hepatocytes by treating HepG2 cells with AFC, a specific inhibitor of ICMT. Our results demonstrate that AFC exposure leads to ERK1/2 inhibition, which is associated with increased DGAT2 expression and elevated intracellular TG accumulation. Since ICMT is the methyltransferase specifically involved in posttranslational modification of Ras protein, these results suggest that ERK1/2 inhibition is a mechanistic link between abnormal methionine metabolism and DGAT2 upregulation in the liver. These observations also imply that the beneficial effects of betaine and folate supplementation in ALD may result from their ability to activate ERK1/2 and thereby attenuate DGAT2 upregulation by improving hepatic methionine metabolism. This is indeed validated by our study with betaine supplementation, in which we found that betaine supplementation improves liver injury and hepatic fat accumulation in AF mice, in parallel with improved methionine metabolism, alleviated hepatic ERK1/2 suppression, and attenuated hepatic DGAT2
overexpression.
Hepatic lipid metabolism is complex and dynamically regulated. Excessive TG accumulation in the liver originates from an imbalance between TG synthesis and removal via mitochondrial beta-oxidation and VLDL secretion. In line with previous reports (21) (22) (23) , in this study we demonstrate increased SREBP-1c
protein abundance in the liver of AF mice (Fig 3D & E) , an indication of enhanced de novo FA synthesis.
Moreover, increased plasma FA levels suggest that FA from adipose tissue lipolysis contributes to the intrahepatic FA pool for TG synthesis. Although in the present study we did not directly measure the effect of chronic alcohol exposure on VLDL secretion and mitochondrial beta-oxidation of FA, elevated plasma ketone bodies and fasting TG concentrations in AF mice provide indirect evidence of enhanced FA oxidation and VLDL secretion in the early stages of ALD. The elevated plasma TG content is in line with the observed hepatic DGAT1 expression (data not shown), which plays an important role in VLDL secretion (37) . These data altogether suggest that both TG synthesis and disposal are enhanced in the early stage of alcoholic liver disease and that fatty liver develops when the capability of the liver to remove TG dose not compensate for 16 the increased synthesis.
In conclusion, we demonstrate that upregulation of hepatic DGAT2 by chronic alcohol exposure contributes to the development of ALD. Abnormal hepatic methionine metabolism, specifically the suppression of transmethylation reactions, plays a mechanistic role in alcohol-induced DGAT2 upregulation by suppressing MEK/ERK1/2 activation. Therefore, inhibition of ERK1/2 activation represents a critical link between methionine metabolism and fatty liver development via upregulation of hepatic DGAT2
expression.
Legends Data are means ± SD (n = 4). * P < 0.05. PF: pair-fed; AF: alcohol-fed. 
